Compare Stocks: OMER, GRFS, ACAD, and DYN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$30.57 +3.1%	$26.32	$19.69 ▼ $30.96	$5.11B	0.81	1.81 million shs	1.52 million shs
DYN Dyne Therapeutics	$26.34 +1.3%	$23.99	$11.92 ▼ $27.31	$4.85B	1.07	1.88 million shs	1.46 million shs
GRFS Grifols	$8.09 +1.3%	$7.61	$6.96 ▼ $10.23	$5.44B	0.67	532,175 shs	375,056 shs
OMER Omeros	$19.28 -0.2%	$12.12	$3.94 ▼ $19.65	$1.40B	2.54	2.47 million shs	1.31 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.51%	+2.21%	+19.36%	+39.46%	+15.19%
DYN Dyne Therapeutics	-0.42%	-0.61%	+6.34%	+43.20%	+106.60%
GRFS Grifols	-0.12%	+2.83%	+5.41%	-0.25%	-21.36%
OMER Omeros	+0.26%	+11.29%	+97.34%	+65.84%	+339.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$30.57 +3.1%	$26.32	$19.69 ▼ $30.96	$5.11B	0.81	1.81 million shs	1.52 million shs
DYN Dyne Therapeutics	$26.34 +1.3%	$23.99	$11.92 ▼ $27.31	$4.85B	1.07	1.88 million shs	1.46 million shs
GRFS Grifols	$8.09 +1.3%	$7.61	$6.96 ▼ $10.23	$5.44B	0.67	532,175 shs	375,056 shs
OMER Omeros	$19.28 -0.2%	$12.12	$3.94 ▼ $19.65	$1.40B	2.54	2.47 million shs	1.31 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.51%	+2.21%	+19.36%	+39.46%	+15.19%
DYN Dyne Therapeutics	-0.42%	-0.61%	+6.34%	+43.20%	+106.60%
GRFS Grifols	-0.12%	+2.83%	+5.41%	-0.25%	-21.36%
OMER Omeros	+0.26%	+11.29%	+97.34%	+65.84%	+339.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.78	Moderate Buy	$34.36	12.40% Upside
DYN Dyne Therapeutics	2.87	Moderate Buy	$34.42	30.66% Upside
GRFS Grifols	1.67	Reduce	$10.00	23.61% Upside
OMER Omeros	2.67	Moderate Buy	$38.00	97.10% Upside

Current Analyst Ratings Breakdown

Latest OMER, GRFS, ACAD, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$37.00 ➝ $38.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$27.00 ➝ $28.00
8/25/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $40.00
8/17/2026	GRFS Grifols	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
8/17/2026	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $49.00
8/17/2026	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/12/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/12/2026	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $41.00
8/10/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00
8/10/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $39.00
8/6/2026	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.92	$0.92 per share	33.25	$7.25 per share	4.22
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
GRFS Grifols	$8.51B	0.65	$1.43 per share	5.65	$12.64 per share	0.64
OMER Omeros	N/A	N/A	$1.87 per share	10.30	($1.71) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	13.77	32.18	23.23	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
GRFS Grifols	$454.82M	$0.19	42.58	6.18	0.29	5.54%	6.21%	2.39%	11/10/2026 (Estimated)
OMER Omeros	-$3.35M	$1.28	15.06	17.06	N/A	N/A	-164.92%	69.41%	11/12/2026 (Estimated)

Latest OMER, GRFS, ACAD, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	OMER Omeros	-$0.2683	$0.02	+$0.2883	$0.15	$12.69 million	$28.53 million
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
7/30/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
GRFS Grifols	$0.09	1.11%	N/A	47.37%	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A

Latest OMER, GRFS, ACAD, and DYN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/19/2026	GRFS Grifols	special	$0.0945		7/2/2026	7/2/2026	7/9/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
DYN Dyne Therapeutics	0.28	12.02	12.02
GRFS Grifols	1.10	2.37	0.81
OMER Omeros	N/A	1.95	1.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
DYN Dyne Therapeutics	96.68%
GRFS Grifols	N/A
OMER Omeros	48.79%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
DYN Dyne Therapeutics	9.46%
GRFS Grifols	0.19%
OMER Omeros	10.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	172.31 million	127.16 million	Optionable
DYN Dyne Therapeutics	100	186.75 million	169.08 million	Optionable
GRFS Grifols	25,247	680.58 million	679.28 million	Optionable
OMER Omeros	210	72.39 million	64.79 million	Optionable

OMER, GRFS, ACAD, and DYN Headlines

Recent News About These Companies

David Borges Sells 906 Shares of Omeros (NASDAQ:OMER) Stock

2 hours ago | marketbeat.com

David Borges Sells 10,000 Shares of Omeros (NASDAQ:OMER) Stock

2 hours ago | marketbeat.com

Omeros (NASDAQ:OMER) Hits New 52-Week High - Should You Buy?

August 25 at 12:39 PM | marketbeat.com

Omeros (OMER) Just Flashed Golden Cross Signal: Do You Buy?

August 25 at 10:56 AM | zacks.com

Omeros Corporation (OMER) Stock Price, News, Quote & History - Yahoo Finance

August 25 at 9:01 AM | finance.yahoo.com

Omeros (NASDAQ:OMER) Director Thomas Cable Sells 15,000 Shares of Stock

August 22 at 7:37 AM | insidertrades.com

Insider Shake-Up at Omeros as Key Director Sells Off a Chunk of Shares

August 21, 2026 | tipranks.com

Omeros (NASDAQ:OMER) Director Thomas Cable Sells 15,000 Shares

August 21, 2026 | marketbeat.com

Omeros (OMER) Q2 2026 Earnings Call Transcript

August 20, 2026 | finance.yahoo.com

Omeros (NASDAQ:OMER) Sets New 52-Week High - Still a Buy?

August 19, 2026 | marketbeat.com

Insider Selling: Omeros (NASDAQ:OMER) CAO Sells 5,000 Shares of Stock

August 18, 2026 | insidertrades.com

Omeros (NASDAQ:OMER) CAO David Borges Sells 5,000 Shares of Stock

August 17, 2026 | marketbeat.com

Research Analysts Offer Predictions for Omeros Q3 Earnings

August 17, 2026 | americanbankingnews.com

HC Wainwright Comments on Omeros' Q3 Earnings (NASDAQ:OMER)

August 17, 2026 | marketbeat.com

FY2029 Earnings Forecast for Omeros Issued By HC Wainwright

August 16, 2026 | americanbankingnews.com

Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

August 15, 2026 | defenseworld.netD

Omeros Corporation (NASDAQ:OMER) Given Average Rating of "Moderate Buy" by Brokerages

August 15, 2026 | americanbankingnews.com

Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 15, 2026 | marketbeat.com

Omeros (NASDAQ:OMER) Rating Increased to Buy at Wall Street Zen

August 15, 2026 | americanbankingnews.com

Wall Street Zen Upgrades Omeros (NASDAQ:OMER) to Buy

August 15, 2026 | marketbeat.com

Omeros (NASDAQ:OMER) Reaches New 1-Year High on Earnings Beat

August 15, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OMER, GRFS, ACAD, and DYN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$30.57 +0.92 (+3.10%)

Closing price 04:00 PM Eastern

Extended Trading

$30.92 +0.34 (+1.13%)

As of 05:43 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Dyne Therapeutics NASDAQ:DYN

$26.34 +0.35 (+1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$26.34 0.00 (-0.02%)

As of 04:15 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Grifols NASDAQ:GRFS

$8.09 +0.10 (+1.25%)

Closing price 04:00 PM Eastern

Extended Trading

$8.09 0.00 (0.00%)

As of 04:10 PM Eastern

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Omeros NASDAQ:OMER

$19.28 -0.04 (-0.21%)

Closing price 04:00 PM Eastern

Extended Trading

$19.17 -0.11 (-0.57%)

As of 05:36 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OMER, GRFS, ACAD, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OMER, GRFS, ACAD, and DYN Earnings

Compare Dividends

Latest OMER, GRFS, ACAD, and DYN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OMER, GRFS, ACAD, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OMER, GRFS, ACAD, and DYN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

Dyne Therapeutics NASDAQ:DYN

Grifols NASDAQ:GRFS

Omeros NASDAQ:OMER

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools